Form 4: Cytokinetics Executive Fady Ibraham Malik Reports Stock Option Exercise and Sale
SEC Form 4
Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, exercised stock options and sold shares on October 30, 2024, according to a Form 4 filing.
Summary
- On October 30, 2024, Fady Ibraham Malik, an Executive Vice President at Cytokinetics Inc., executed transactions involving the company's common stock.
- Malik exercised options to acquire 5,300 shares of common stock at a price of $7.96 per share.
- Simultaneously, Malik sold 5,300 shares at $51.90 and 2,000 shares at $51.93.
- Following these transactions, Malik directly owns 114,920 shares of Cytokinetics Inc.
- Malik also holds options to purchase 15,900 shares.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, reflecting routine transactions. It doesn't inherently convey positive or negative sentiment.
Industry Context
Insider transactions are routinely monitored by investors to gauge executive sentiment regarding the company's prospects. Option exercises followed by sales are a common way for executives to realize compensation.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership.
Key Dates
| Date | Description |
|---|---|
| 03/26/2015 | Date the Non-Qualified Stock Option (Right to Buy) was exercisable |
| 02/26/2025 | Expiration date of the Non-Qualified Stock Option (Right to Buy) |
| 10/30/2024 | Date of stock option exercise and stock sales |
| 10/31/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.